Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients

Luisella Bocchio-Chiavetto; Roberta Zanardini; Marco Bortolomasi; Maria Abate; Matilde Segala; Mario Giacopuzzi; Marco Andrea Riva; Eleonora Marchina; Patrizio Pasqualetti; Jorge Perez; Massimo Gennarelli

doi:10.1016/j.euroneuro.2006.04.010

Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients

Luisella Bocchio-Chiavetto, Roberta Zanardini, Marco Bortolomasi, Maria Abate, Matilde Segala, Mario Giacopuzzi, Marco Andrea Riva, Eleonora Marchina, Patrizio Pasqualetti, Jorge Perez, Massimo Gennarelli

Research output: Contribution to journal › Article › peer-review

Abstract

Several findings have suggested that the neurotrophin BDNF could contribute to clinical efficacy of antidepressant treatments. The purpose of this study was to analyse if ECT operates a modulation of serum BDNF levels in a sample of drug resistant depressed patients. The results obtained show significantly higher serum levels of BDNF following ECT. More specifically, while no change occurred in the whole sample between T0 (baseline) and T1 (after ECT) (p = 0.543) a significant increase has been identified at T2, one month after the end of ECT (p = 0.002). However, the BDNF augmentation was evident even between T0 and T1 in a subgroup of patients who has low baseline BDNF levels. Although future researches are needed, the results herein presented show for the first time that ECT is associated with changes in serum BDNF and further support the possible involvement of BDNF in antidepressant therapies.

Original language	English
Pages (from-to)	620-624
Number of pages	5
Journal	European Neuropsychopharmacology
Volume	16
Issue number	8
DOIs	https://doi.org/10.1016/j.euroneuro.2006.04.010
Publication status	Published - Dec 2006

Keywords

BDNF
Drug resistant
ECT
MADRS
Major depression
Serum

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health
Biological Psychiatry
Neurology
Pharmacology
Psychology(all)

Access to Document

10.1016/j.euroneuro.2006.04.010

Fingerprint Dive into the research topics of 'Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients'. Together they form a unique fingerprint.

Cite this

Bocchio-Chiavetto, L., Zanardini, R., Bortolomasi, M., Abate, M., Segala, M., Giacopuzzi, M., Riva, M. A., Marchina, E., Pasqualetti, P., Perez, J., & Gennarelli, M. (2006). Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. European Neuropsychopharmacology, 16(8), 620-624. https://doi.org/10.1016/j.euroneuro.2006.04.010

Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. / Bocchio-Chiavetto, Luisella ; Zanardini, Roberta; Bortolomasi, Marco; Abate, Maria; Segala, Matilde; Giacopuzzi, Mario; Riva, Marco Andrea; Marchina, Eleonora; Pasqualetti, Patrizio; Perez, Jorge; Gennarelli, Massimo.

In: European Neuropsychopharmacology, Vol. 16, No. 8, 12.2006, p. 620-624.

Research output: Contribution to journal › Article › peer-review

Bocchio-Chiavetto, L , Zanardini, R, Bortolomasi, M, Abate, M, Segala, M, Giacopuzzi, M, Riva, MA, Marchina, E, Pasqualetti, P, Perez, J & Gennarelli, M 2006, 'Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients', European Neuropsychopharmacology, vol. 16, no. 8, pp. 620-624. https://doi.org/10.1016/j.euroneuro.2006.04.010

Bocchio-Chiavetto, Luisella ; Zanardini, Roberta ; Bortolomasi, Marco ; Abate, Maria ; Segala, Matilde ; Giacopuzzi, Mario ; Riva, Marco Andrea ; Marchina, Eleonora ; Pasqualetti, Patrizio ; Perez, Jorge ; Gennarelli, Massimo. / Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. In: European Neuropsychopharmacology. 2006 ; Vol. 16, No. 8. pp. 620-624.

@article{c160836c8825447b832d3e150d8b3381,

title = "Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients",

abstract = "Several findings have suggested that the neurotrophin BDNF could contribute to clinical efficacy of antidepressant treatments. The purpose of this study was to analyse if ECT operates a modulation of serum BDNF levels in a sample of drug resistant depressed patients. The results obtained show significantly higher serum levels of BDNF following ECT. More specifically, while no change occurred in the whole sample between T0 (baseline) and T1 (after ECT) (p = 0.543) a significant increase has been identified at T2, one month after the end of ECT (p = 0.002). However, the BDNF augmentation was evident even between T0 and T1 in a subgroup of patients who has low baseline BDNF levels. Although future researches are needed, the results herein presented show for the first time that ECT is associated with changes in serum BDNF and further support the possible involvement of BDNF in antidepressant therapies.",

keywords = "BDNF, Drug resistant, ECT, MADRS, Major depression, Serum",

author = "Luisella Bocchio-Chiavetto and Roberta Zanardini and Marco Bortolomasi and Maria Abate and Matilde Segala and Mario Giacopuzzi and Riva, {Marco Andrea} and Eleonora Marchina and Patrizio Pasqualetti and Jorge Perez and Massimo Gennarelli",

year = "2006",

month = dec,

doi = "10.1016/j.euroneuro.2006.04.010",

language = "English",

volume = "16",

pages = "620--624",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier Science B.V.",

number = "8",

}

TY - JOUR

T1 - Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients

AU - Bocchio-Chiavetto, Luisella

AU - Zanardini, Roberta

AU - Bortolomasi, Marco

AU - Abate, Maria

AU - Segala, Matilde

AU - Giacopuzzi, Mario

AU - Riva, Marco Andrea

AU - Marchina, Eleonora

AU - Pasqualetti, Patrizio

AU - Perez, Jorge

AU - Gennarelli, Massimo

PY - 2006/12

Y1 - 2006/12

N2 - Several findings have suggested that the neurotrophin BDNF could contribute to clinical efficacy of antidepressant treatments. The purpose of this study was to analyse if ECT operates a modulation of serum BDNF levels in a sample of drug resistant depressed patients. The results obtained show significantly higher serum levels of BDNF following ECT. More specifically, while no change occurred in the whole sample between T0 (baseline) and T1 (after ECT) (p = 0.543) a significant increase has been identified at T2, one month after the end of ECT (p = 0.002). However, the BDNF augmentation was evident even between T0 and T1 in a subgroup of patients who has low baseline BDNF levels. Although future researches are needed, the results herein presented show for the first time that ECT is associated with changes in serum BDNF and further support the possible involvement of BDNF in antidepressant therapies.

AB - Several findings have suggested that the neurotrophin BDNF could contribute to clinical efficacy of antidepressant treatments. The purpose of this study was to analyse if ECT operates a modulation of serum BDNF levels in a sample of drug resistant depressed patients. The results obtained show significantly higher serum levels of BDNF following ECT. More specifically, while no change occurred in the whole sample between T0 (baseline) and T1 (after ECT) (p = 0.543) a significant increase has been identified at T2, one month after the end of ECT (p = 0.002). However, the BDNF augmentation was evident even between T0 and T1 in a subgroup of patients who has low baseline BDNF levels. Although future researches are needed, the results herein presented show for the first time that ECT is associated with changes in serum BDNF and further support the possible involvement of BDNF in antidepressant therapies.

KW - BDNF

KW - Drug resistant

KW - ECT

KW - MADRS

KW - Major depression

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=33751252587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751252587&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2006.04.010

DO - 10.1016/j.euroneuro.2006.04.010

M3 - Article

C2 - 16757154

AN - SCOPUS:33751252587

VL - 16

SP - 620

EP - 624

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 8

ER -